

10/560282

10/560282
AP13 RECEIVED BY USPTO 16 DEC 2005
PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Docket No: Q91632

Takahiro KURAMOCHI, et al.

Appln. No.: Based on PCT/JP04/008479

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: December 05, 2005

Examiner: Unknown

For: BENZAMIDE DERIVATIVE OR SALT THEREOF

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith on CD-ROM, along with a copy of the corresponding Communication from a Foreign Patent Office, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

A copy of an International Search Report in a counterpart application is submitted herewith. The USPTO should receive copies of the references cited in the International Search Report from the International Bureau. Applicant will furnish any missing references upon request.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: Based on PCT/JP04/008479
Attorney Docket No.: Q91632

on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents (International Search Report for PCT/JP04/008479 dated September 7, 2004), together with an English-language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office.

Also Applicant's have advised that the following documents correspond to each other:

PCT publication	US corresponding Patent
WO 2002/008221	US 2002132853
WO 2003/014064	US 2004259875
WO 2003/068749	none
WO 2001/021577	none
WO 2003/035624	US 2005209213
WO 98/41508	US 2001016657 US 2003144320 US 2004209912 US 6841560
WO 9748683	US 6110934
WO 2003/055848	US 2005154230
JP2003/55209	none
JP2002/3370	none
WO 2004/072069	none
WO 2004/056774	none
WO 2004/108133	US 2005004133

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

10/560282

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: Based on PCT/JP04/008479
Attorney Docket No.: Q91632

1AP13 Rec'd PCT/PTO 12 DEC 2005

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Mark Boland
Registration No. 32,197

Date: December 12, 2005

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/560,282
Confirmation Number	Unknown
Filing Date	December 05, 2005
First Named Inventor	Takahiro KURAMOCHI
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	Q91632

Sheet

1

of

1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number			Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)	Publication Date MM-DD-YYYY	
/KHI/	US 2002132853			09-2000	Raiannan et al.
	US 2004259875			12-2004	Yura et al.
	US 2005209213			11-2005	Imura et al.
	US 2001016657			09-2001	Thompson et al.
	US 2003144320			07-2003	Thompson et al.
	US 2004209912			10-2004	Thompson et al.
	US 6841560			01-2005	Thompson et al.
	US 6110934			09-2000	Harling et al.
	US 2005154230			07-2005	Yura et al.
	US 2005004133			01-2005	Makings et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Translation ⁴
		Country Code ³	Number ⁴	Kind Code ³ (if known)		
/KHI/	WO 03/55848	A2	03/55848	A2	07-10-2003	BAYER AKTIENGESELLSCHAFT
	WO 03/68749	A1	03/68749	A1	08-21-2003	GLAXO GROUP LIMITED
	WO 02/8221	A2	02/8221	A2	01-31-2002	NEUROGEN CORP
	JP 2003-55209	A	2003-55209	A	02-26-2003	Bayer AG
	JP 2002-3370	A	2002-3370	A	01-09-2002	Takeda Chemical Industries, Ltd.
	WO 03/014064	A1	03/014064	A1	02-20-2003	BAYER AKTIENGESELLSCHAFT
	WO 03/035624	A1	03/035624	A1	05-01-2003	TAKEDA CHEMICAL INDUSTRIES
	WO 98/41508	A1	98/41508	A1	09-24-1998	SMITHKLINE BEECHAM PLC
	WO 97/48683	A1	97/48683	A1	12-24-1997	SMITHKLINE BEECHAM PLC
	WO 2004/108133	A2	2004/108133	A2	12-16-2004	VERTEX PHARMACEUTICALS INCORPORATED
	WO 01/021577	A2	01/021577	A2	03-29-2001	TAKEDA CHEMICAL INDUSTRIES
	WO 04/072069	A1	04/072069	A1	08-26-2004	GLAXO GROUP LIMITED
	WO 04/056774	A2	04/056774	A2	07-08-2004	NEUROGEN CORPORATION

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁴

Examiner Signature	/Kahsay Habte/	Date Considered	06/16/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov. MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.